Found: 12
Select item for more details and to access through your institution.
Empagliflozin as add-on to metformin in people with Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2015, v. 32, n. 12, p. 1555, doi. 10.1111/dme.12814
- By:
- Publication type:
- Article
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 10, p. 1034, doi. 10.1111/dom.12734
- By:
- Publication type:
- Article
Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 3, p. 241, doi. 10.1111/dom.12597
- By:
- Publication type:
- Article
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 12, p. 1180, doi. 10.1111/dom.12572
- By:
- Publication type:
- Article
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial ( EASE-1).
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 928, doi. 10.1111/dom.12494
- By:
- Publication type:
- Article
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 936, doi. 10.1111/dom.12503
- By:
- Publication type:
- Article
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 7, p. 665, doi. 10.1111/dom.12464
- By:
- Publication type:
- Article
Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 7, p. 699, doi. 10.1111/dom.12469
- By:
- Publication type:
- Article
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2) inhibitor, in subjects with renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 3, p. 215, doi. 10.1111/dom.12182
- By:
- Publication type:
- Article
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 2, p. 147, doi. 10.1111/dom.12188
- By:
- Publication type:
- Article
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 2, p. 118, doi. 10.1111/dom.12183
- By:
- Publication type:
- Article
Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex.
- Published in:
- Neurogastroenterology & Motility, 2007, v. 19, n. 9, p. 744, doi. 10.1111/j.1365-2982.2007.00975.x
- By:
- Publication type:
- Article